Journal: Molecular Cancer

Article Title: Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential

doi: 10.1186/s12943-025-02393-9

Figure Lengend Snippet: TG-1 suppresses CD30-CD30L-mediated B-NHL proliferation by targeting the non-canonical NF-κB pathway. Relative cell viability of Jeko-1 ( A ) and Raji ( B ) cells was assessed following incubation with 5 and 10 µg/ml of CD30, 10 µg/ml of CD30 pretreated with 25 µM TG-1, or 10 µg/ml of CD30 pretreated with 1 µg/ml CD30L antibodies for 4–6 h at 37 °C, as determined by MTT assays. ( C ) Relative cell viability of Granta-519 cells was evaluated after exposure to 10 µg/ml of CD30 that had been pretreated with the CD30L plasmid (1 µg), as well as with CD30 alone, using MTT assays. The expression levels of NFκB-2, IKKα, phosphorylated IKKα, and RELB in Jeko-1 ( D ) and Raji ( E ) cells were evaluated using Western blot analysis after treatment with 10 µg/ml CD30, preceded by pretreatment with either 25 µM TG-1 or1 µg/ml CD30L antibodies. ( F , G ) The protein expression levels of NFκB-2, IKKα, phosphorylated IKKα, and RELB in D and E were quantified using ImageJ. GAPDH served as an internal control. ( H-O ) Immunofluorescence was used to measure the expression levels of NFκB-2 and RELB in Jeko-1 ( H and I ) and Raji ( L and M ) cells following treatment with 10 µg/ml CD30, with a preceding pretreatment of either 25 µM TG-1 or1 µg/ml CD30L antibodies. Scale bar = 20 μm. ( J , K , N , and O ) The normalized fluorescence intensity for H , I , L , and M , respectively. ( P-S ) The relative cell viability of Jeko-1 ( P ), Raji ( Q ), Su-4 ( R ), and Granta-519 ( S ) cells was evaluated after exposure to combinations of 10 µg/ml CD30 and 200 nM IKK16, as determined by MTT assays. Data shown in this figure are the mean values (± SD) from three independent experiments. Statistically significant differences with P < 0.05 were considered significant (# P ≥ 0 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001)

Article Snippet: Treatments included 25 μM TG-1 or Random peptides, recombinant human CD30 protein (HY-P70023, MedChemExpress, NJ, USA) at varying concentrations, and IKK16 (0-500 nM; HY-13687, ChemExpress, China), either alone or in combination, for 24 h at 37 °C.

Techniques: Incubation, Plasmid Preparation, Expressing, Western Blot, Control, Immunofluorescence, Fluorescence

Journal: Molecular Cancer

Article Title: Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential

doi: 10.1186/s12943-025-02393-9

Figure Lengend Snippet: Schematic illustration of the interaction between TG-1-DKK, F-TG-1-AuNPs, and F-TG-1-AuNPs + DOX with CD30L-positive B-NHL cells. Our in vitro experiments have shown that CD30 interacts with CD30L on B-NHL cells, resulting in the promotion of B cell proliferation and the suppression of cell death. Nanoparticles functionalized with the TG-1 peptide selectively bind to CD30L. This binding disrupts the CD30-CD30L interaction, inhibiting CD30L-mediated reverse signaling and leading to a decrease in proliferation. Furthermore, the conjugation of TG-1 with the anti-cancer peptide DKK enhances cell lysis by targeting CD30L. In vivo investigations have demonstrated that FITC-labeled TG-1 can identify and inhibit tumor cell proliferation through the bloodstream. Additionally, F-TG-1-AuNPs + DOX effectively inhibit tumor growth in vivo

Article Snippet: Treatments included 25 μM TG-1 or Random peptides, recombinant human CD30 protein (HY-P70023, MedChemExpress, NJ, USA) at varying concentrations, and IKK16 (0-500 nM; HY-13687, ChemExpress, China), either alone or in combination, for 24 h at 37 °C.

Techniques: In Vitro, Binding Assay, Conjugation Assay, Lysis, In Vivo, Labeling

Journal: Nature Communications

Article Title: Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis

doi: 10.1038/s41467-019-14144-8

Figure Lengend Snippet: a Locus plots showing association with asthma where the lead variant p.Cys273Tyr (rs2230624) is colored in purple. Other variants are colored by degree of correlation ( r 2 ) with the lead variant. b Protein simple WES analysis of CD30 expression in cell lysates from HeLa cells overexpressing CD30 wild-type or variant p.Cys273Tyr CD30; graph showing ratio of CD30 precursor/mature intensity. c Surface expression of CD30 on HeLa cells over-expressing wild-type or p.Cys273Tyr CD30 measured by flow cytometry, displayed as geometric mean of fluorescense intensity (gMFI). Histogram showing a representative CD30 surface expression p.Cys273Tyr (red) and CD30 WT (blue). d sCD30 levels (ng/ml) in cell culture supernatant from HeLa cells over-expressing wild-type or p.Cys273Tyr CD30. e Surface expression of CD30 on stimulated PBMCs from heterozygous p.Cys273Tyr carriers and age and gender matched non-carriers, measured by flow cytometry, displayed as gMFI. Histogram showing a representative CD30 surface expression from one pair of PBMCs in heterozyogus CD30 p.Cys273Tyr carrier (red) and age and gender matched non-carrier (blue). f sCD30 levels (ng/ml) in cell culture supernatant of PBMCs from p.Cys273Tyr heterozygotes and non-carriers. The dots in plots b – d represent individual experiments. The dots in plots e and f represent individual donors. Lines in panel b – d indicate median level. In plots e and f the line between carriers and non-carriers indicated age and gender matched pairs.. Two-tailed Wilcoxon matched-pairs signed rank test was used to test for significant differences in PBMCs. Two-tailed paired t -test was used to test for significant differences in HeLa cells. Source data are provided as a Source Data file.

Article Snippet: Full-length CD30 cDNA ( NM_001243 ) in pCMV6-Entry Myc-DDK tagged mammalian expression vector was obtained from Origene (RC219819).

Techniques: Variant Assay, Expressing, Flow Cytometry, Cell Culture, Two Tailed Test

Journal: Aesthetic surgery journal

Article Title: IL-9 Is a Biomarker of BIA-ALCL Detected Rapidly by Lateral Flow Assay.

doi: 10.1093/asj/sjae137

Figure Lengend Snippet: Figure 3. CD30 lateral flow assay. (A) CD30 standards were diluted from 0 to 10 ng/mL in a benign seroma. (B) Correlation of CD30 concentration with TL/CL ratio (r2 = 0.72, y = 0.05x + 0.7, P = .02). (C) Comparison of CD30 in benign and ALCL seromas (benign, 0.198 ± 0.036 [n = 15] vs ALCL, 0.779 ± 0.083 [n = 11]; P < .0001, t-test). CL, control line; TL, test line.

Article Snippet: Similarly, CD30 LFA strips were made by striping mouse anti-CD30 antibody (R&D Systems, catalog number MAB2291).

Techniques: Lateral Flow Assay, Concentration Assay, Comparison, Control

Journal: Leukemia

Article Title: Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.

doi: 10.1038/leu.2011.265

Figure Lengend Snippet: Figure 5 Stimulation of NF-kB signaling in GSI XII treated L540cy cells. (a) HRS cells were seeded in fresh conditioned medium taken from untreated cells after 96 h culture before GSI XII treatment. Viability of cells was determined 24 h later. Immunoblotting of p52 (upper panel), and viability (lower panel) of GSI XII-treated L540cy cells cultured in fresh and conditioned medium. (b) Immunoblotting of p52 and cleaved PARP (left panel) and viability of L540cy cells (right panel) after stimulation through anti-CD30 antibodies (with and without GSI XII treatment).

Article Snippet: Blots Leukemia were incubated with monoclonal rabbit anti-Notch1, anti-p50/ p105, anti-p65 antibodies (Epitomics, Burlingame, CA, USA), anti-cleaved Notch1, rabbit polyclonal anti-p52/p100, antiphospho-p100, anti-RelB, anti-c-Rel, anti-poly-(ADP-ribose) polymerase, anti-cleaved poly-(ADP-ribose) polymerase (Asp214) antibodies (Cell Signaling Technologies, Frankfurt, Germany), anti-human CD30 (R&D Systems) or mouse monoclonal anti-tubulin antibodies (Sigma, Deisenhofen, Germany).

Techniques: Western Blot, Cell Culture